Saint Medical Technology, a Nanjing-based medical device maker specializing in valvular disease solutions, has reportedly raised “tens of millions” of renminbi in a Pre-Series B financing round. The round was led by Jinpu Intelligent Manufacturing Fund, with participation from Wuxi Capital and Hexingcheng Fund. The proceeds will be used to implement a closed-loop industry consisting of digital medicine, innovative devices, and medical services in the field of structural heart disease. Previously, the company raised RMB 100 million (USD 13.3 million) in a Series A financing round.
Lead Product and Pipeline
Saint Medical’s lead product, the structural fit transcatheter aortic valve system (Xcor), has entered clinical trials. Additionally, Tavigator CDSS, a structural decision support system for heart disease developed by its subsidiary, is also in clinical use. The company’s pipeline includes several innovative products undergoing animal experiments and product testing, such as the suture-free expandable biological valve system (Alive), transcatheter bicuspid/tricuspid valve replacement system (Neocor), and automatic release balloon dilation interventional valve system (Infinicor).
Future Plans
With the new funding, Saint Medical aims to accelerate the development and commercialization of its innovative medical devices and digital solutions for structural heart disease. This strategic move will help the company expand its market presence and enhance its capabilities in providing comprehensive treatment options for patients with valvular heart disease.-Fineline Info & Tech
